Urokinase Plasminogen Activator
Molecular and cellular studies of the role of urokinase plasminogen activator in cutaneous wound healing
... 1999), urokinase plasminogen activator (Jensen and Rodeck, 1993), the a 2 integrin subunit (Chen e t al, 1993) and K6 and K16 (Jiang e t al, 1993), suggesting m ultiple roles for these growth factors ...
221
Soluble urokinase plasminogen activator receptor predicts mortality in exacerbated COPD
... the urokinase plas- minogen activator receptor (uPAR) is involved in the pathogenesis (both small airway fibrosis and emphy- sema) of COPD through complex molecular pathways and gene expression patterns ...
8
Preclinical evaluation of a urokinase plasminogen activator receptor-targeted nanoprobe in rhesus monkeys
... of urokinase plasminogen activator receptor-targeted magnetic iron oxide (IO) nanoparticles (uPAR-targeted human ATF-IONPs) into clinical applications, we conducted a pilot study to evaluate the ...
10
Reactive oxygen species regulate urokinase plasminogen activator expression and cell invasion via mitogen-activated protein kinase pathways after treatment with hepatocyte growth factor in stomach cancer cells
... Reactive oxygen species regulate urokinase plasminogen activator expression and cell invasion via mitogen-activated protein kinase pathways after treatment with hepatocyte growth facto[r] ...
9
Expression and activity of the urokinase plasminogen activator system in canine primary brain tumors
... the urokinase plasminogen activator receptor (uPAR), a glycosylphosphatidylinositol-anchored protein family member, and the activity of its ligand, urokinase-type plasminogen ...
9
Regulation of urokinase plasminogen activator and plasminogen activator inhibitor-1 in murine breast cancer cells
... of urokinase plasminogen activator (uPA) and plasminogen activator inhibitor (PAI)-1 in two murine mammary adencocarcinoma cell lines: metastatic 4T1 cells and non-metastatic 67NR ...
140
Soluble urokinase plasminogen activator receptor (suPAR) and natural phosphorylcholine IgM antibodies in patients at clinical onset of diabetes mellitus
... soluble urokinase plasmi- nogen activator receptor (suPAR) and natural IgM antibodies directed against phosphorylcho- line (αPC-IgM) in Swedish diabetic patients (n = 164) and in healthy control subjects (n ...
8
Urokinase Plasminogen Activator Receptor (uPAR) Targeted Nuclear Imaging and Radionuclide Therapy
... proenzyme, pro-uPA, in such a manner that the acti- vation cascade can occur directly on the cell surface. Activated uPA converts inactive plasminogen into active plasmin, which degrades various components of the ...
9
Role of urokinase plasminogen activator and plasminogen activator inhibitor mRNA expression as prognostic factors in molecular subtypes of breast cancer
... nase plasminogen activator (uPA) and plasminogen activator inhibitor-1 (PAI-1) in fresh-frozen tumor tissue from primary breast cancers by a commercially available ...
9
Integrin dependent induction of functional urokinase receptors in primary T lymphocytes
... gen activator/plasmin system in normal T cell ...for urokinase plasminogen activator (uPAR) were not expressed in resting T lymphocytes, but could be efficiently induced at the mRNA and ...
10
Effect of hypoxia on the expression of CCN2, PLAU, PLAUR, SLURP1, PLAT and ITGB1 genes in ERN1 knockdown U87 glioma cells
... (tissue plasminogen activator), CCN2 (CCN family member 2) и ITGB1 (integrin β-1), а также к снижению уровня экспрессии мрнк PLAU (urokinase plasminogen activator), PLAUR ...
11
Introduction of a prognostic biomarker to strengthen risk stratification of acutely admitted patients: rationale and design of the TRIAGE III cluster randomized interventional trial
... Soluble urokinase plasminogen activator receptor (suPAR) is a prognostic biomarker with potential use in the EDs. The suPAR blood level reflects immune activation and it is strongly associated with ...
7
SuPAR predicts postoperative complications and mortality in patients with asymptomatic aortic stenosis
... Background We evaluated whether early measurement of soluble urokinase plasminogen activator receptor (suPAR) could predict future risk of postoperative complications in initially a[r] ...
6
Use of the prognostic biomarker suPAR in the emergency department improves risk stratification but has no effect on mortality: a cluster-randomized clinical trial (TRIAGE III)
... soluble urokinase plasminogen activator receptor (suPAR) for risk stratification in the emergency department reduces mortality in acutely admitted ...
10
A ligand free, soluble urokinase receptor is present in the ascitic fluid from patients with ovarian cancer
... We have identified a soluble form of the human urokinase plasminogen activator (uPA) receptor (uPAR) in the ascitic fluids from patients with ovarian cancer. After purification of uPAR from the ...
9
Common TNF α, IL 1β, PAI 1, uPA, CD14 and TLR4 polymorphisms are not associated with disease severity or outcome from Gram negative sepsis
... Methods: Clinical data and DNA from consecutive adult patients with culture proven Gram negative bacteremia admitted to a Danish hospital between 2000 and 2002. Analysis for commonly described SNPs of tumor necrosis-α, ...
7
uPA/uPAR and SERPINE1 in head and neck cancer: role in tumor resistance, metastasis, prognosis and therapy
... the plasminogen activator system in head and neck squamous cell carcinoma (HNSCC), particularly of its uPA (urokinase plasminogen activator) / uPAR (urokinase plasminogen ...
16
Factors influencing the cell adhesion and invasion capacity of Mycoplasma gallisepticum
... as plasminogen (P7999), urokinase plasminogen activa- tor ...fibronectins, plasminogen, and collagens, 200 μg/ml for heparin, 100 μg/ml for EACA, 20 U/ml for urokinase ...
8
Association of dietary soy with expression of various pro-inflammatory genes in porcine phagocytes
... of urokinase plasminogen activator (u-PA), its receptor (u-PAR) and plasminogen activator inhibitors type 1 and 2 (PAI-1 and PAI-2) in blood monocytes and neutrophils from 72 day old ...
8
Leptin, IL-6, and suPAR reflect distinct inflammatory changes associated with adiposity, lipodystrophy and low muscle mass in HIV-infected patients and controls
... soluble urokinase plasminogen activator receptor (suPAR) were associated distinctively with adiposity, lipodystrophy and sarcopenia, in HIV-infected patients and healthy ...
11